Cudarolimab
Cudarolimab (IBI101) is a completely human anti-OX40 (CD134, a co stimulating molecule expressed by activated immune cells) antibody. Cudarolimab inhibits the binding of OX40 to its ligand OX40L. Cudarolimab has antitumor activity and can be used in cancer related research[1].
Product Specifications
CAS Number
2244739-29-3
Product Name Alternative
IBI101
UNSPSC
12352203
Target
Orexin Receptor (OX Receptor)
Type
Inhibitory Antibodies
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/cudarolimab.html
Purity
95.00
Solubility
10 mM in DMSO
Smiles
[Cudarolimab]
Molecular Weight
(145.94 kDa)
References & Citations
[1]Kuang Z, et al. Development and characterization of a novel anti-OX40 antibody for potent immune activation. Cancer Immunol Immunother. 2020 Jun;69 (6) :939-950.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![5,9-Dibromo-7,7-diphenyl-7H-benzo[c]fluorene](https://cdn.genprice.uk/genprice/uk/genprice2.webp)